Thyroid Cancer | Tumor

CURE’s thyroid cancer page is an extensive resource of cancer information featuring the latest thyroid cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on thyroid cancer.

FDA Approves Retevmo for Some Adults and Children With Thyroid Cancer

June 12th 2024, 7:00pm

Article

The Food and Drug Administration granted a traditional approval to Retevmo for adult and pediatric patients 2 years old and older with advanced or metastatic RET fusion-positive thyroid cancer.

FDA Approves Retevmo for RET-Positive Pediatric Cancers

May 29th 2024, 4:41pm

Article

Retevmo was approved for childhood metastatic medullary thyroid, thyroid and solid tumors with RET mutations or gene fusions.

Retevmo Improves RET-Mutant Thyroid Cancer Outcomes

August 25th 2023, 1:00pm

Article

Progression-free survival improved with Retevmo as the initial treatment for patients with advanced RET-mutant medullary thyroid cancer.

Addressing Unmet Needs in Differentiated Thyroid Cancer

May 12th 2022, 1:00pm

Video

Before closing out their discussion on differentiated thyroid cancer, patients and health care professionals alike consider unmet needs in this space.

Treating Radioiodine-Refractory DTC After Progression on Lenvatinib

May 5th 2022, 1:15pm

Video

A brief discussion on therapeutic options one may consider after progression on lenvatinib therapy for iodine-refractory DTC.

Practical Advice and Resources for Patients on Systemic Therapy for DTC

May 5th 2022, 1:00pm

Video

Shared practical advice for patients who may be undergoing treatment for iodine-refractory differentiated thyroid cancer.

Communicating With Care Providers While on Therapy for DTC

April 28th 2022, 1:20pm

Video

Discussion on how best to communicate with care providers while undergoing therapy for iodine-refractory differentiated thyroid cancer.

Radioiodine-Refractory DTC: Dosing Considerations for Lenvatinib Therapy

April 28th 2022, 1:00pm

Video

Considerations for how dosing and dose reductions can be used to optimize use of lenvatinib for iodine-refractory DTC.

Receiving Lenvatinib Therapy for Iodine-Refractory DTC

April 21st 2022, 1:15pm

Video

Expert and patient perspectives on receiving lenvatinib therapy for iodine-refractory differentiated thyroid cancer.

Radioiodine-Refractory DTC: An Overview of Work-up and Treatment Options

April 21st 2022, 1:00pm

Video

Health care specialists share insight on the work-up of patients with iodine-refractory differentiated thyroid cancer and how this may affect systemic therapy options.